Fractionated Radioimmunotherapy With (90)Y-epratuzumab in
Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II
Study
- Results Presented at the 12th Congress of European HematologyAssociation (EHA) - VIENNA, Austria, June 11, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that data presented at the 12th Congressof EHA in Vienna, Austria, showed positive responses in patie...
Promising Results with Epratuzumab and Chemotherapy in Children
with Acute Lymphoblastic Leukemia
- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with
epratuzumab plus standardchemotherapy is feasible...